Journal
IMMUNITY
Volume 51, Issue 1, Pages 43-+Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2019.04.017
Keywords
-
Categories
Funding
- Careers in Immunology postdoctoral fellowship from the American Association of Immunologists
- NIH [T32AI089474, R01GM121583, P01DK091222, R01GM086550, R21AR069908, R01GM127609, P41GM103311]
- National Cancer Institute [ACB-12002]
- National Institute of General Medical Sciences [AGM-12006]
- DOE Office of Science [DE-AC02-06CH11357]
Ask authors/readers for more resources
Gasdermin D (GSDMD) is an effector molecule for pyroptosis downstream of canonical and non-canonical inflammasome signaling pathways. Cleavage of GSDMD by inflammatory caspases triggers the oligomerization and lipid binding by its N-terminal domain, which assembles membrane pores, whereas its C-terminal domain binds the N-terminal domain to inhibit pyroptosis. Despite recent progress in our understanding of the structure and function of the murine gasdermin A3 (mGSDMA3), the molecular mechanisms of GSDMD activation and regulation remain poorly characterized. Here, we report the crystal structures of the full-length murine and human GSDMDs, which reveal the architecture of the GSDMD N-terminal domains and demonstrate distinct and common features of autoinhibition among gasdermin family members utilizing their beta 1-beta 2 loops. Disruption of the intramolecular domain interface enhanced pyroptosis, whereas mutations at the predicted lipid-binding or oligomerization surface reduced cytolysis. Our study provides a framework for understanding the autoinhibition, lipid binding, and oligomerization of GSDMD by using overlapping interfaces.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available